ATE265226T1 - Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin- abhängiger krankheiten - Google Patents
Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin- abhängiger krankheitenInfo
- Publication number
- ATE265226T1 ATE265226T1 AT98932727T AT98932727T ATE265226T1 AT E265226 T1 ATE265226 T1 AT E265226T1 AT 98932727 T AT98932727 T AT 98932727T AT 98932727 T AT98932727 T AT 98932727T AT E265226 T1 ATE265226 T1 AT E265226T1
- Authority
- AT
- Austria
- Prior art keywords
- asparaginase
- succinogenes
- asparagine
- methods
- succinogenes asparaginase
- Prior art date
Links
- 102000015790 Asparaginase Human genes 0.000 title abstract 6
- 108010024976 Asparaginase Proteins 0.000 title abstract 6
- 241000605939 Wolinella succinogenes Species 0.000 title abstract 5
- 229960003272 asparaginase Drugs 0.000 title abstract 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 2
- 229960001230 asparagine Drugs 0.000 abstract 2
- 235000009582 asparagine Nutrition 0.000 abstract 2
- 230000003211 malignant effect Effects 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000010933 acylation Effects 0.000 abstract 1
- 238000005917 acylation reaction Methods 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 238000002372 labelling Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000009145 protein modification Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- C12N9/82—Asparaginase (3.5.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4908597P | 1997-06-09 | 1997-06-09 | |
| PCT/US1998/011905 WO1998056410A1 (en) | 1997-06-09 | 1998-06-09 | Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE265226T1 true ATE265226T1 (de) | 2004-05-15 |
Family
ID=21957977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98932727T ATE265226T1 (de) | 1997-06-09 | 1998-06-09 | Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin- abhängiger krankheiten |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6251388B1 (de) |
| EP (1) | EP0988050B1 (de) |
| AT (1) | ATE265226T1 (de) |
| AU (1) | AU752370B2 (de) |
| CA (1) | CA2295980A1 (de) |
| DE (1) | DE69823501T2 (de) |
| ES (1) | ES2217566T3 (de) |
| WO (1) | WO1998056410A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6991788B1 (en) | 1997-06-09 | 2006-01-31 | Childrens Hospital Los Angeles | Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence |
| US6689762B1 (en) | 1998-02-09 | 2004-02-10 | Enzon Pharmaceuticals, Inc. | Composition and methods for treatment of HIV infection |
| DE69909747T2 (de) * | 1998-02-09 | 2004-04-15 | Enzon Pharmaceuticals, Inc. | Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen |
| EP1181045A4 (de) * | 1999-04-02 | 2003-04-23 | Los Angeles Childrens Hospital | Verwendung von asparaginase und glutaminase zur behandlung von autoimmunerkrankungen sowie erkrankungen der abstossung von knochenmark und empfänger |
| AU6894400A (en) * | 1999-08-06 | 2001-03-05 | Enzon Pharmaceuticals Inc. | Composition and methods for treatment of HIV infection |
| AU2002332371A1 (en) * | 2001-08-22 | 2003-03-10 | Gosudarstvennoe Uchrezhdenie Nauchno-Issledovatelsky Institut Biomeditsinskoy Khimii Im. Orekhovicha | Recombinant l-asparaginase less thanigreater thanerwinia caratovoraless than/igreater than |
| JP2008545831A (ja) * | 2005-05-27 | 2008-12-18 | フォームフォームフォーム リミテッド | 手動成形可能な材料 |
| US7531343B2 (en) * | 2006-01-30 | 2009-05-12 | Georgia State University Research Foundation, Inc. | Induction and stabilization of enzymatic activity in microorganisms |
| US7943549B2 (en) | 2007-04-02 | 2011-05-17 | Georgia State University Research Foundation, Inc. | Biological-based catalyst to delay plant development processes |
| FI20070455A0 (fi) * | 2007-06-08 | 2007-06-08 | Reagena Ltd Oy | Menetelmä syöpäsairauksien tai tulehdussairauksien hoitoon |
| US8815232B2 (en) | 2008-08-26 | 2014-08-26 | Kyon Biotech Ag | Compositions and methods for treating cancer |
| EP2766478A4 (de) | 2011-10-10 | 2015-06-17 | Los Angeles Childrens Hospital | Neue asparaginase und verfahren zur behandlung von erkrankungen im zusammenhang mit asparaginabhängigkeit |
| CA2903501A1 (en) | 2013-03-14 | 2014-10-02 | Georgia State University Research Foundation, Inc. | Preventing or delaying chill injury response in plants |
| WO2014160354A1 (en) | 2013-03-14 | 2014-10-02 | Georgia State University Research Foundation, Inc. | Inhibiting or reducing fungal growth |
| WO2015024593A1 (en) * | 2013-08-20 | 2015-02-26 | Chr. Hansen A/S | Method for growth of bacterial cells |
| RU2562166C1 (ru) * | 2014-10-09 | 2015-09-10 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") | ГИБРИДНЫЙ БЕЛОК НА ОСНОВЕ L-АСПАРАГИНАЗЫ Wolinella succinogenes, ШТАММ Escherichia coli - ПРОДУЦЕНТ ГИБРИДНОГО БЕЛКА (ВАРИАНТЫ) И СПОСОБ ПОЛУЧЕНИЯ ГИБРИДНОГО БЕЛКА, ОБЛАДАЮЩЕГО ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ |
| WO2018085493A1 (en) * | 2016-11-04 | 2018-05-11 | Georgia State University Research Foundation, Inc. | Endotoxin free asparaginase |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1807303A1 (de) * | 1968-11-06 | 1970-06-04 | Bayer Ag | Partiell acylierte L-Asparaginasen |
| DE2039061A1 (de) * | 1970-08-06 | 1972-02-10 | Bayer Ag | Partiell amidierte L-Asparaginasen |
| US5322678A (en) * | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
| US5693516A (en) * | 1995-11-27 | 1997-12-02 | Novo Nordisk Biotech, Inc. | Method for solubilizing proteins in organic solvents |
-
1998
- 1998-06-09 ES ES98932727T patent/ES2217566T3/es not_active Expired - Lifetime
- 1998-06-09 DE DE69823501T patent/DE69823501T2/de not_active Expired - Lifetime
- 1998-06-09 AU AU82544/98A patent/AU752370B2/en not_active Ceased
- 1998-06-09 EP EP98932727A patent/EP0988050B1/de not_active Expired - Lifetime
- 1998-06-09 AT AT98932727T patent/ATE265226T1/de not_active IP Right Cessation
- 1998-06-09 US US09/094,435 patent/US6251388B1/en not_active Expired - Lifetime
- 1998-06-09 CA CA002295980A patent/CA2295980A1/en not_active Abandoned
- 1998-06-09 WO PCT/US1998/011905 patent/WO1998056410A1/en active IP Right Grant
-
2001
- 2001-01-31 US US09/773,260 patent/US20020102251A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0988050B1 (de) | 2004-04-28 |
| ES2217566T3 (es) | 2004-11-01 |
| DE69823501D1 (de) | 2004-06-03 |
| CA2295980A1 (en) | 1998-12-17 |
| WO1998056410A1 (en) | 1998-12-17 |
| WO1998056410A9 (en) | 1999-04-08 |
| AU8254498A (en) | 1998-12-30 |
| US6251388B1 (en) | 2001-06-26 |
| DE69823501T2 (de) | 2005-04-07 |
| EP0988050A1 (de) | 2000-03-29 |
| US20020102251A1 (en) | 2002-08-01 |
| AU752370B2 (en) | 2002-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE265226T1 (de) | Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin- abhängiger krankheiten | |
| EA200400312A1 (ru) | АНТАГОНИСТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ hTNFSF13b ЧЕЛОВЕКА | |
| ATE383865T1 (de) | Apolipoprotein a-i agonisten und deren verwendung zur behandlung dyslipidämischer erkrankungen | |
| DE3750451D1 (de) | Rekombinanter menschlicher endothelzellenwachstumsfaktor. | |
| CY1111120T1 (el) | Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση | |
| ES8602121A1 (es) | Procedimiento para producir un vehiculo de expresion para la formacion de uroquinasa humana | |
| DE69730038D1 (de) | Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen | |
| DE60331546D1 (de) | Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung | |
| DE69735502D1 (de) | Mutanten des lag-3 proteins, ihre expression und verwendung | |
| SE8902532D0 (sv) | Bestaemning av plasmaproteiner | |
| HUP0500637A2 (hu) | Neublasztin polimer konjugátumai és alkalmazási eljárásai | |
| ATE153069T1 (de) | Vektoren und zusammensetzungen zur expression von glykosilationsmutanten des menschlichen proteins- c | |
| DE69331813T4 (de) | Verfahren zur Detektion und Behandlung von Individuen mit abnormal hla-a2/tyrosinase-peptidantigenen exprimierenden Zellen | |
| WO2001088085A3 (en) | Novel bee venom polypeptides and methods of use thereof | |
| ATE112317T1 (de) | Bcrf1-proteine als inhibitoren von interferon- g(g). | |
| DE60036555D1 (de) | Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter | |
| WO2000063415A8 (en) | Dna encoding the human vanilloid receptor vr1 | |
| ATE310828T1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
| ATE384739T1 (de) | Für den menschlichen vanilloid-rezeptor vr3 kodierende dns | |
| EA200401390A1 (ru) | N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения | |
| ES8802441A1 (es) | Procedimiento para preparar laminina humana | |
| HUP9900789A2 (hu) | Lefelé irányuló szabályozásra rezisztens C3 konvertáz | |
| DE59410423D1 (de) | Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose | |
| ATE293994T1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
| ATE414776T1 (de) | Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |